 The objective of this phase 3 study is to assess the efficacy and safety of 0.05 difluprednate ophthalmic emulsion DFBA in patients with endogenous anterior uveitis, in comparison with 0.1 betamethasone sodium phosphate ophthalmic solution BP. 